Sanofi's Lyxumia plus insulin shows promise in diabetes study

05/31/2011 | Reuters · Fox Business

A Phase III trial found that adding Sanofi's diabetes drug candidate Lyxumia to basal insulin improved body mass and blood glucose level while not heightening the risk of hypoglycemia in patients with type 2 diabetes. Lyxumia, a GLP-1 agonist licensed from Zealand Pharma, would compete against Victoza and Amylin from Novo Nordisk and Byetta from Eli Lilly and Co.

View Full Article in:

Reuters · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL